Sanofi
French pharma giant built around Dupixent, its blockbuster immunology drug.
The call
Sanofi's growth still rides on one drug, Dupixent, with patent cover into the 2040s and rival biologics still years from approval.
Sanofi makes prescription medicines, with its biggest seller being Dupixent, which treats skin and lung diseases. It is hard to copy because the company has government approval documents, patent protection lasting decades, and relationships with hospitals and insurance companies that would take years for a rival to rebuild. The main risk is that its top drug loses patent protection around 2031, so whether the company buys or builds new blockbuster drugs in the next year or two will determine if it can stay a growth story or just becomes a stable dividend stock.
Why
01
AI pressure: None apparent. AI speeds up Sanofi's own drug discovery and trial design but cannot skip FDA/EMA approval or clinical proof. Could AI do the core job? Unlikely.
02
Bigger players: AstraZeneca and GSK COPD biologics, plus China-based IL-4Ra rivals. Competing biologics for the same allergic and inflammatory conditions are in development but none has been approved or taken Dupixent share yet. Could a giant copy it? No, they are blocked.
03
What protects it. Dupixent has over 50 patents running to 2045 and regulatory approval hurdles keep biosimilars out until at least 2031.
What would change this call
Sanofi Q2 2026 earnings (July 30, 2026) show Dupixent growth rate versus ~+33% Q1 2026 pace. Whether Dupixent's growth is still accelerating or beginning to decelerate.
Garijo's ~$30B war chest deployed on late-stage immunology/rare-disease M&A by Q4 2026. Whether Sanofi is diversifying beyond Dupixent before the 2031 biosimilar cliff.
AstraZeneca, GSK, or a China-based IL-4Rα biologic gains regulatory approval in Dupixent's indications. Whether a rival biologic has cleared the regulatory bar to compete directly with Dupixent.
Garijo's ~$30B war chest deployed on late-stage immunology/rare-disease M&A by Q4 2026. Whether Sanofi is diversifying beyond Dupixent before the 2031 biosimilar cliff.
AstraZeneca, GSK, or a China-based IL-4Rα biologic gains regulatory approval in Dupixent's indications. Whether a rival biologic has cleared the regulatory bar to compete directly with Dupixent.
Key numbers
- FY2025 net sales: 43.63 billion euros, up 9.9% CER
- Dupixent Q1 2026 sales up 33% to about 4.2 billion euros
- Dupixent patents: 50+ extending protection to 2045
Named risks
- Dupixent biosimilar competition projected from 2031 to 2033, threatening single-franchise dependence.
- Pipeline setbacks including tolebrutinib FDA rejection and mixed Phase 2/3 data on amlitelimab, balinatunfib, itepekimab.
- Zantac litigation still has 847 pending federal cases despite April 2026 summary judgment win, appeal risk remains.
- Leadership transition under new CEO Garijo (started April 29, 2026) creates strategic uncertainty on M&A deployment.
- Emerging COPD biologic competition from AstraZeneca and GSK could pressure Dupixent's newest indication.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Regeneron | contesting | Co-markets Dupixent but runs parallel competing pipeline assets, as of 2026-04-28 |
| AstraZeneca | contesting | Developing rival COPD biologic against Dupixent, per 2024-10-15 reporting still relevant in 2026 |
| GSK | contesting | Developing competing COPD biologic versus Dupixent, per industry analysis through 2026 |
| Merck (MSD) | contesting | Enflonsia approved to compete with Sanofi's Beyfortus in RSV, per 2025-08-11 profile |
| China domestic IL-4Ra rivals | gaining on | Flagged as near-to-mid-term risk to Dupixent per 2026-05-20 competitive landscape analysis |
Questions people ask
- Is Sanofi profitable in 2026?
- Yes. Sanofi reported FY2025 net sales of €43.63 billion (+9.9% CER) and business EPS of €7.83 (+15.0% CER) as of December 31, 2025, and Q1 2026 sales grew 13.6% CER, with Q2 2026 results due July 30, 2026.
- Could AI replace Sanofi?
- No. AI tools from Aqemia, Owkin, and Earendil Labs speed up drug discovery inside Sanofi's R&D as of 2026, but Dupixent alone carries 50+ patents to 2045 and eight regulatory approvals that no AI model can obtain without clinical trials and agency sign-off.
- Who is Sanofi's biggest competitor?
- Regeneron co-markets Dupixent yet runs a parallel pipeline, while AstraZeneca and GSK are developing rival COPD biologics and Merck's Enflonsia competes with Sanofi's Beyfortus in RSV, per reporting through 2026.
- Who owns Sanofi and what is it worth?
- Sanofi is publicly traded (Euronext: SAN, Nasdaq: SNY) with no controlling parent; BlackRock Fund Advisors holds roughly 23.3 million shares and Capital Research about 22.6 million, with market cap near $106 billion as of July 2026.
- What happened to Sanofi's CEO in 2026?
- Paul Hudson departed February 17, 2026 after the board declined to renew his mandate, following the FDA's tolebrutinib rejection; Belén Garijo, a 15-year Sanofi veteran and former Merck KGaA CEO, took over as CEO on April 29, 2026.
- Is Dupixent facing biosimilar competition soon?
- Not yet. Analysts project biosimilar competition to Dupixent as early as 2031 per Regeneron or 2033 for eczema per Leerink, while the drug still grew 33% year-over-year to about $4.9 billion in Q1 2026, backed by 50+ patents extending to 2045.
Timeline
- 2026-07-17Aqemia collaboration expanded with new target, potential payments up to $140 million
- 2026-06-05Multi-year agentic AI collaboration with Owkin announced (K Pro, five-year license)
- 2026-04-29Belén Garijo becomes Sanofi CEO
- 2026-04-22FDA approves Dupixent for children 2-11 with chronic spontaneous urticaria
- 2026-04-14Delaware Superior Court grants summary judgment for Sanofi in Zantac litigation
- 2026-02-17CEO Paul Hudson departs after board declines to renew mandate
- 2026-02-12Garijo named incoming CEO; Sanofi shares fall about 6%
- 2026-02-10Sanofi completes acquisition of Dynavax Technologies at $15.50/share
- 2026-01-29Sanofi reports FY2025 net sales of €43.63 billion, +9.9% CER
- 2025-04-30Opella consumer healthcare divestiture to CD&R completed, ~€10 billion net cash
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- strong sales and EPS growth. Continued profitable growth expected in 2026 (2026-01-29)
- Garijo starts as Sanofi CEO with window to ease reliance on Dupixent (2026-04-28)
- double-digit sales and business EPS growth (2026-04-23)
- Belén Garijo to become Chief Executive Officer of Sanofi (2026-02-12)
- Sanofi names Belén Garijo CEO in leadership shake-up; stock down 6% (2026-02-12)
- Sanofi completes the acquisition of Dynavax (2026-02-10)
- Sanofi announces the signing of a share buyback mandate for up to €1 billion (2026-02-03)
- Dupixent Growth as a Biosimilar Timeline Play (2026-05-15)
- SAN) Revenue (2026-06-18)
- Aqemia and Sanofi Expand Their Research Collaboration (2026-07-17)
- Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi (2026-07-19)
- AI Biologics Drug Discovery: Earendil Labs $787M Funding (2026-07-16)